who are fit for treatment. We present the experiences of our two supraregional penile cancer referral centres.
INTRODUCTION AND OBJECTIVES:
Relapsed and metastatic penile (mPSCC) and uterine cervical squamous cell carcinoma (mCSCC) are aggressive forms of malignancy with currently limited systemic treatment options. We performed a comprehensive genomic profiling (CGP) study to compare the genomic alterations (GA) and their potential impact on targeted and immunotherapy options.
METHODS: 78 cases of metastatic mPSCC and 604 cases of mCSCC underwent CGP on a minimum of 50 ng of DNA using a hybridcapture, adaptor ligation-based next-generation sequencing assay with a mean coverage depth of >500X. The results were analyzed for all classes of genomic alterations (GA), including base substitutions, insertions and deletions (short variants; SV), fusions, and copy number changes including amplifications (amp) and homozygous deletions. Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci.
RESULTS: The median age of the men with mPSCC was higher than the women with mCSCC. The HPVþ/CDKN2A-status was significantly more frequent in the mCSCC than mPSCC cases. The GA/ tumor frequencies were similar for both tumor types. TP53 mutations were more common in mPSCC, which may be associated with the loss of an original HPVþ status. TERT, NOTCH1 and FAT1 GA were more frequent in mPSCC whereas PIK3CA GA were more common in mCSCC. MTOR pathway targets (GA in STK11, FBXW7 and PTEN) were more common in mCSCC. MSI-High status was extremely rare in all cases, but the relatively high frequencies of TMB > 10/20 mut/Mb in both mPSCC and mCSCC were noteworthy. Examples of patients with mCSCC and mPSCC responding to targeted and immunotherapies will be presented.
CONCLUSIONS: Although mCSCC and mPSCC share a variety of genomic features, the 2 tumor types can nonetheless be sharply differentiated on CGP. The TP53, CDKN2A and HPV status of the tumor types differ significantly with viral identification much higher in the mCSCC group. There are opportunities for targeted therapies in both groups predominantly identified in the MTOR pathway. The relatively high numbers of cases with significantly elevated TMB in both mPSCC and mCSCC suggest that immunotherapies might be of benefit in a subset of patients.
Source of Funding: None

MP49-13 IMPACT OF MISMANAGEMENT ON QUALITY OF LIFE IN TESTICULAR CANCER SURVIVORS
Joshua Aizen*, Ciro Andolfi, Chicago, IL; Madeleine Burg, Los Angeles, CA; Nimrod Barashi, Brittany Adamic, Craig Labbate, Chicago, IL; Siamak Daneshmand, Los Angeles, CA; Scott Eggener, Chicago, IL INTRODUCTION AND OBJECTIVES: Despite well-established guidelines for the treatment of testicular cancer, nonguideline directed care (NGDC) is seen in 30% of patients and has been identified as a significant predictor of disease relapse. However, the potential impact of mismanagement on patient quality of life (QoL) has yet to be established. We aimed to compare QoL among testicular cancer survivors who received NGDC against patients who received guideline directed care (GDC).
METHODS: We retrospectively reviewed data from men presenting with testicular cancer to two academic medical centers from 2007-2016. NGDC was defined as management differing from current National Comprehensive Care Network (NCCN) recommendations. Cases of NGDC were systematically described. Patients were later asked to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EORTC QLQ-C30, a previously validated oncology-specific survey. These were filled out either in person or via mail-in !6 months after treatment.
RESULTS: A total of 120 men completed the EORTC QLQ-C30 questionnaire. The cohort had a mean age of 33.6AE11.4 years and was predominantly Caucasian (100 [83.3%] (18.8% v 37.3%, p[0.02) , and were more likely to relapse (34.4% v 12.8%, p<0.01). In patients who received GDC, both self-reported global health status and physical functioning were superior when compared with patients receiving NGDC (p[0.015 and p[0.013, respectively) . Men who were mismanaged were also more likely to report financial difficulties (p<0.01). The remainder of the function and symptom scores were not significantly different between groups (Table 1) .
CONCLUSIONS: In addition to treatment delay, avoidable morbidity, and higher rates of relapse, NGDC of testicular cancer leads to inferior global QoL, worse physical functioning, and more financial stress. This data reinforces the effort to increase awareness and implementation of recognized guidelines among providers.
